By Bhanvi Satija and Patrick Wingrove
Aug 8 (Reuters) - Increased manufacturing capacity for Eli Lilly's highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion on Thursday, and its share jumped as much as 14%.
Facing issue in account approval? email us at info@ipt.pw
Log in to comment or register here.